Aclaris Therapeutics – $105 Million Follow-On Offering

Reston – November 30, 2016 – Cooley advised Aclaris Therapeutics on its $104.7 million follow-on offering, which includes the full exercise of the underwriters’ option to purchase additional shares.

Aclaris, which trades on the NASDAQ Global Select Market under the symbol “ACRS,” is a clinical-stage specialty pharmaceutical company focused on identifying, developing and commercializing novel drugs to address unmet needs in dermatology.

Cooley advised Aclaris on its $63.3 million IPO in October 2015 and a $20 million private placement in May 2016.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Brian Leaf Partner, Reston
Brent Siler Partner, Washington, DC
Div Gupta Partner, New York
Mark Ballantyne Associate, Reston
Katie Kazem Associate, Reston
Natasha Leskovsek Partner, Washington, DC
Mark Windfeld-Hansen Partner, Palo Alto
Phil Mitchell Partner, New York